According to Fortune Business Insights, the global targeted protein degradation market size was valued at USD 5.95 billion in 2025 and is projected to grow from USD 5.88 billion in 2026 to USD 12.44 billion by 2034, exhibiting a CAGR of 9.81% during the forecast period. North America dominated the global targeted protein degradation market with a market share of 52.10% in 2025.
The targeted protein degradation market is emerging as an important area within the pharmaceutical and biotechnology industries because of its potential to address disease-associated proteins that may be difficult to target through conventional drug discovery approaches. Targeted protein degradation uses specialized therapeutic approaches to identify and eliminate specific proteins within cells rather than simply inhibiting their activity. This approach is attracting interest among researchers and pharmaceutical companies because it may provide opportunities to address previously challenging biological targets. Growing investment in drug discovery, increasing research activity in molecular biology, and advances in protein science are supporting the development of targeted protein degradation technologies. Pharmaceutical companies and biotechnology firms are investigating degraders for applications across oncology, immunology, neurological disorders, and other therapeutic areas. The growing number of research collaborations, licensing arrangements, and development programs is also supporting market expansion. Improvements in chemical biology, proteomics, structural biology, and drug delivery are enabling researchers to develop increasingly sophisticated degradation approaches. The targeted protein degradation market is therefore benefiting from expanding research pipelines and increasing interest in therapeutic strategies that can selectively remove disease-related proteins.
Continue reading for more details:
https://www.fortunebusinessinsights.com/targeted-protein-degradation-market-115361
The targeted protein degradation market is segmented by technology, therapeutic area, and region. Based on technology, the market includes proteolysis-targeting chimeras, molecular glues, and other targeted degradation approaches. Proteolysis-targeting chimeras represent an important technology because they are designed to bring a target protein into proximity with cellular degradation machinery, resulting in targeted removal of the protein. Molecular glues represent another promising approach because they can facilitate interactions between proteins and cellular degradation systems without necessarily requiring the same structural configuration used by conventional degrader molecules. Researchers are continuing to investigate both approaches to identify suitable therapeutic applications. Based on therapeutic area, the targeted protein degradation market includes oncology, immunology, neurological disorders, and other disease areas. Oncology represents a major area of research because targeted degradation may provide new strategies for addressing proteins involved in tumor growth and disease progression. Researchers are also investigating applications in immunological disorders and neurological diseases where conventional therapeutic approaches may face limitations. By end user, the ecosystem includes pharmaceutical companies, biotechnology companies, academic institutions, and research organizations. Pharmaceutical and biotechnology companies are investing in discovery and development programs, while academic institutions contribute to target identification, mechanism research, and technology development. Collaboration between these groups is supporting innovation and accelerating the translation of laboratory research into potential therapeutic applications.
The targeted protein degradation market is experiencing growth because of increasing interest in new therapeutic mechanisms and the limitations associated with conventional drug discovery approaches. Traditional therapies often focus on inhibiting the activity of proteins, whereas targeted protein degradation aims to remove specific proteins from cells. This mechanism has attracted significant research interest because it may create opportunities to address proteins that have historically been difficult to modulate using conventional approaches. Pharmaceutical companies are expanding research programs to evaluate targeted degradation across multiple therapeutic areas. Oncology remains an important focus because many disease-driving proteins can be challenging to inhibit effectively. Researchers are investigating whether targeted degradation can provide durable biological effects by eliminating proteins rather than temporarily blocking their activity. Advances in molecular design and drug discovery are also supporting the development of new degrader molecules. Improved understanding of protein-protein interactions, cellular degradation pathways, and molecular structure is helping researchers optimize candidate compounds. Increasing collaborations between biotechnology companies and large pharmaceutical organizations are contributing to technology development, research financing, and clinical advancement. Licensing agreements and strategic partnerships are allowing companies to combine specialized targeted degradation platforms with broader drug development capabilities. Academic research is also supporting the identification of new degradation mechanisms and potential therapeutic targets. Advances in proteomics and computational drug design are providing additional tools for studying protein behavior and identifying suitable targets. As the scientific understanding of targeted protein degradation continues to develop, pharmaceutical companies are increasingly exploring its potential as a drug discovery platform. The combination of technological advances, expanding research pipelines, strategic collaborations, and growing interest in novel therapeutic mechanisms is supporting the continued development of the targeted protein degradation market.